Log in to save to my catalogue

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04927424v1

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell lymphoma. In a previous pilot study of tisagenlecleucel in r/r follicular lymphoma (FL), 71% of patients achieved a complete response (CR). Here we report the primary...

Alternative Titles

Full title

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_04927424v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04927424v1

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X,1744-7933

DOI

10.1038/s41591-021-01622-0

How to access this item